Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Operating Expenses (2021 - 2025)

Kezar Life Sciences' Operating Expenses history spans 5 years, with the latest figure at $11.7 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 46.62% year-over-year to $11.7 million; the TTM value through Sep 2025 reached $65.5 million, down 36.79%, while the annual FY2024 figure was $90.6 million, 23.49% down from the prior year.
  • Operating Expenses for Q3 2025 was $11.7 million at Kezar Life Sciences, down from $14.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $34.6 million in Q4 2023 and bottomed at $11.7 million in Q3 2025.
  • The 5-year median for Operating Expenses is $18.9 million (2022), against an average of $19.9 million.
  • The largest annual shift saw Operating Expenses skyrocketed 72.65% in 2023 before it crashed 46.62% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $14.1 million in 2021, then soared by 42.05% to $20.0 million in 2022, then surged by 72.65% to $34.6 million in 2023, then tumbled by 37.66% to $21.6 million in 2024, then tumbled by 45.67% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Operating Expenses are $11.7 million (Q3 2025), $14.6 million (Q2 2025), and $17.6 million (Q1 2025).